REVERSING EPITHELIAL TO MESENCHYMAL TRANSITION BY TARGETED EPIGENETIC EDITING IN BREAST CANCER

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1147528

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Cancer cell spread around the body involves changes in the cells which allow them to migrate into blood vessels, travel and then invade other organs, a process called epithelial mesenchymal transition (EMT). EMT also makes cells less sensitive to our best treatments. EMT involves switching on genes that activate these changes and switching off genes that silence them. We will develop therapy that will reverse this process, both reducing cancer spread and making cancer treatment more effective.

Funded Activity Details

Start Date: 01-01-2018

End Date: 01-01-2022

Funding Scheme: Project Grants

Funding Amount: $1,352,322.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Epigenetics (incl. Genome Methylation and Epigenomics)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

biotechnology | breast cancer | epigenetics | epithelial-mesenchymal transition (EMT) | gene expression

Related Links